Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience. Academic Article uri icon

Overview

publication date

  • May 1, 2018

Research

keywords

  • Aminopyridines
  • Antineoplastic Agents
  • Gene Expression Regulation, Neoplastic
  • Isocitrate Dehydrogenase
  • Leukemia, Myeloid, Acute
  • Mutation
  • Triazines

Identity

Scopus Document Identifier

  • 85048243191

PubMed ID

  • 29851927

Additional Document Info

volume

  • 16

issue

  • 5